1. INTRON A Redipen

INTRON A Redipen 18 MIU Solution for injection
INTRON A Redipen 30 MIU Solution for injection
INTRON A Redipen 60 MIU Solution for injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each INTRON A Redipen 18 MIU contains interferon alfa-2b 15 million IU/mL (6 doses of 3 million IU, 0.2 mL per dose)
Each INTRON A Redipen 30 MIU contains interferon alfa-2b 25 million IU/mL (6 doses of 5 million IU, 0.2 mL per dose)
Each INTRON A Redipen 60 MIU contains interferon alfa-2b 50 million IU/mL (6 doses of 10 million IU, 0.2 mL per dose)

INTRON A is a sterile, stable formulation of highly purified interferon alfa-2b produced by recombinant DNA techniques. Recombinant interferon alfa-2b is a water soluble protein with a molecular weight of approximately 19,300 daltons. It is obtained from a clone of E. coli which has a genetically engineered plasmid containing an interferon alfa-2 gene from human leucocytes. The activity of INTRON A is expressed in terms of International Units (IU). The specific activity of INTRON A is approximately $2.6 \times 10^8$ IU/mg.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

INTRON A Redipen is a preloaded, multi-dose disposable injector and is available in packs of single pens. Each pack also contains 6 needles and 6 swabs.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

INTRON A Redipen is used in the treatment of:
- Hairy cell leukaemia in splenectomised or non-splenectomised patients;
- Kaposi's sarcoma in patients with acquired immune deficiency syndrome (AIDS);
- Chronic myelogenous leukaemia;
- Multiple myeloma;
- Follicular non-Hodgkin's lymphoma;
- Malignant melanoma;
- Chronic hepatitis B in adults;
- Chronic hepatitis C in adults.
4.2 Dose and method of administration

Dose

**Hairy Cell Leukaemia**

The recommended dosage of INTRON A is 2 million IU/m² administered subcutaneously three times a week (every other day). Higher doses are not recommended. Normalisation of one or more haematologic variables usually begins within 2 months of therapy. Improvement in all three haematologic variables (granulocyte count, platelet count and haemoglobin level) may require 6 months or more. Non-splenectomised patients responded similarly to splenectomised patients and showed similar demonstrable improvement in transfusion requirements. This dosage regimen should be maintained unless the disease progresses rapidly or severe intolerance is manifested.

The minimum effective dose of INTRON A has not been established.

**Kaposi's Sarcoma**

The recommended dosage for INTRON A is 30 million IU/m² administered subcutaneously three times a week. This dosage regimen should be maintained indefinitely unless the disease progresses rapidly or severe intolerance is manifested.

**Chronic Myelogenous Leukaemia-Monotherapy**

The recommended dosage of INTRON A Injection is 4 to 5 MIU/m² administered daily subcutaneously. When the white blood count is controlled, the dosage may be administered three times a week (every other day).

The dosage may be adjusted according to patient's tolerance to the medication. This regimen should be maintained unless the disease progresses rapidly or severe intolerance is manifested.

**Multiple Myeloma**

INTRON A Injection should be administered subcutaneously three times a week (every other day) beginning at a dose of 2 MIU/m². Depending upon tolerance, the dosage should be progressively increased weekly to the maximum tolerated dose (5-10 MIU/m²) and administered three times a week. Administration should be continued unless the disease progresses rapidly or severe intolerance is manifested.

**Follicular Non-Hodgkin's Lymphoma**

INTRON A is used adjunctively with chemotherapy in the treatment of follicular lymphomas. The recommended dosage is 5 MIU administered subcutaneously, three times a week (every other day).

**Malignant Melanoma**

INTRON A Redipen is suitable only for the treatment phase involving subcutaneous administration.

As induction therapy, INTRON A is administered intravenously at a dose of 20 million IU/m² daily for five days a week over a four-week period. The calculated INTRON A dose is added to
100 mL of saline solution and administered as a 20-minute infusion. As maintenance treatment, the recommended dose is 10 million IU/m² administered subcutaneously three times a week for 48 weeks.

If severe adverse reactions develop during INTRON A treatment, particularly if granulocytes decrease to <500/mm³ or ALT/AST rises to >5x upper limit of normal, treatment should be temporarily discontinued until the adverse reactions abate. INTRON A treatment should be restarted at 50% of the previous dose. If intolerance persists after dose adjustment or if granulocytes decrease to <250/mm³ or ALT/AST rises to >10x upper limit of normal, INTRON A therapy should be discontinued.

There is no evidence that dose modifications beyond those described will result in maintenance of clinical benefit. For full clinical benefit, patients should be treated at the recommended doses, with dose modification for toxicity as described.

**Chronic Hepatitis B**

The lowest effective dose of INTRON A Injection is 3 MIU three times a week, administered subcutaneously.

Patients with low baseline HBV-DNA (i.e. <100 pcg) have the best response to INTRON A Injection therapy and most responders will show a 50% decrease in HBV-DNA within one month.

Patients at high risk (HBV-DNA >100 pcg), or patients who do not respond within one month may be treated at doses of 5 MIU three times weekly or up to 5 MIU daily.

The dosage may be adjusted according to the patient’s tolerance to medication. With a response the selected regimen should be maintained up to four months, unless severe intolerance develops.

**Chronic Hepatitis C Monotherapy**

The recommended dose is 3 million IU administered subcutaneously three times a week. Most patients who respond demonstrate improvement in ALT levels within 12 to 16 weeks. In these patients, therapy should be continued with 3 million IU three times a week for up to 18 months.

In patients who fail to respond after 12 to 16 weeks of treatment, use of INTRON A Injection should be discontinued.

Current clinical experience in patients who remain on INTRON A Injection for 12 to 18 months indicates that a higher proportion of patients demonstrated a sustained response after longer durations of therapy than those who discontinued therapy after six months.

[See Laboratory Tests under Section 4.4 for tests to be conducted and timing of these tests.]

**Concomitant Therapy**
Paracetamol has been used successfully to alleviate the symptoms of fever and headache which can occur with INTRON A therapy. The recommended paracetamol dosage is 500 mg to 1 g given 30 minutes before administration of INTRON A. The maximum dosage of paracetamol to be given is 1 g four times daily.

Method of administration

Precautions to be taken before handling or administering the medicine

Parenteral drug products should be inspected visually prior to administration. INTRON A Redipen contains a solution that is clear and colourless.

INTRON A REDIPEN IS NOT RECOMMENDED FOR INTRALESIONAL ADMINISTRATION.
EACH INTRON A REDIPEN IS FOR AN INDIVIDUAL PATIENT’S USE ONLY.

INTRON A Redipen contains a pre-filled, multi-dose cartridge for subcutaneous administration. It is designed to deliver fixed doses as required using a simple dial mechanism.

The needles provided in the packaging will be used for the INTRON A Redipen only. A new needle is to be used each time the pen delivers a dose.

During the course of treatment with INTRON A for any indication, if adverse reactions develop, the dosage should be modified or therapy should be discontinued temporarily until the adverse reactions abate. If persistent or recurrent intolerance develops following adequate dosage adjustment, or disease progresses, the treatment with INTRON A should be discontinued.

For maintenance dosage regimens administered subcutaneously, at the discretion of the physician, the patient may self-administer the dose.

Directions for use of Redipen

The Redipen should be at room temperature (15° to 25°C) before administering each dose. The pen should be removed from the refrigerator approximately 30 minutes before administration to allow the injectable solution to reach room temperature.

Each Redipen is intended for a maximum two-week use period and then must be discarded. A new needle must be used for each dose. After each use, the needle should be discarded safely and the Redipen must be returned to the refrigerator immediately. In case the product is left inadvertently at room temperature, a maximum total of 48 hours (two days) of exposure to room temperature is permitted over a two-week use period. Nevertheless, to reduce the risk of microbial contamination, the Redipen should remain stored at 2° to 8°C.

Refer to enclosed package insert for detailed directions on the use of the Redipen injector.
Paediatric population

No data are available.

4.3 Contraindications

A history of hypersensitivity to recombinant interferon alfa-2b or any other components of INTRON A contraindicates its use. Hypersensitivity to other forms of interferon alfa should lead to extreme caution with the use of INTRON A.

Patients with decompensated liver disease, autoimmune hepatitis or a history of autoimmune liver disease, and patients who are immunosuppressed transplant recipients should not be treated with INTRON A for chronic hepatitis. There are reports of worsening liver disease, including jaundice, hepatic encephalopathy, hepatic failure and death following INTRON A therapy in such patients.

Patients with severe renal dysfunction or creatinine clearance less than 50mL/min must not be treated with INTRON A when used in combination with ribavirin.

INTRON A is not intended for use in premature infants or neonates.

4.4 Special warnings and precautions for use

Acute, serious hypersensitivity reactions (e.g. urticaria, angioedema, bronchoconstriction, anaphylaxis) to INTRON A have been observed rarely during INTRON A therapy. If any such reaction develops, the drug should be discontinued and appropriate medical therapy instituted immediately. Transient rashes do not necessitate interruption of treatment.

INTRON A Redipen contains meta cresol as preservative; some patients may experience an allergic reaction to this ingredient.

Moderate to severe adverse experiences may require modification of the patient's dosage regimen, or in some cases, termination of INTRON A therapy.

INTRON A should be used cautiously in patients with debilitating medical conditions, such as those with a history of pulmonary disease (e.g. chronic obstructive pulmonary disease) or diabetes mellitus prone to ketoacidosis. Caution should be observed also in patients with coagulation disorder (e.g. thrombophlebitis, pulmonary embolism) or severe myelosuppression.

Administration of INTRON A in combination with other chemotherapeutic agents may lead to increased risk of toxicity (severity and duration), which may be life-threatening or fatal as a result of the concomitantly administered drug. The most commonly reported potentially life-threatening or fatal adverse events include mucositis, diarrhoea, neutropenia, renal impairment and electrolyte disturbance. Because of the risk of increased toxicity, careful adjustments of doses are required for INTRON A and for the concomitant chemotherapeutic agents.

While fever may be associated with the flu-like syndrome reported commonly during interferon therapy, other causes of persistent fever should not be overlooked.

In patients with liver disease, exacerbation of hepatic enzyme abnormalities may occur. Monitoring of liver function tests is advised. Hepatotoxicity resulting in fatality has been observed rarely. INTRON A increases the risk of hepatic decompensation and death in patients with cirrhosis. Therefore, any patient developing liver function abnormalities during treatment
with INTRON A should be monitored closely and treatment discontinued if signs and symptoms progress.

In patients considered for treatment of hepatitis, a liver biopsy should be performed to document diagnosis and extent of disease. Patients with causes of chronic hepatitis other than chronic hepatitis B or chronic hepatitis C, including autoimmune hepatitis, should be excluded. Prior to initiation of INTRON A therapy, the physician should establish that the patient has compensated liver disease. INTRON A should not be used in patients with decompensated liver disease.

Patients with chronic hepatitis B with evidence of decreasing hepatic synthetic function (e.g. decreasing albumin or prolongation of prothrombin time), who nevertheless meet the criteria for therapy, may be at increased risk of clinical decompensation if a flare of aminotransferases occurs during INTRON A treatment [see Laboratory Tests]. In considering these patients for INTRON A therapy, the potential risks must be evaluated against the potential benefits of treatment.

Results of two studies indicate that the efficacy of interferon therapy remains uncertain in chronic active hepatitis B in children or in adults where the presumed route of transmission is vertical.

Infrequently, patients treated for chronic hepatitis C with INTRON A developed thyroid abnormalities (hypothyroid or hyperthyroid). In clinical trials <1% (4/426) developed thyroid abnormalities. The abnormalities were controlled by conventional therapy for thyroid dysfunction. The mechanism by which INTRON A may alter thyroid status is unknown. Prior to initiation of INTRON A therapy for the treatment of chronic hepatitis C, serum thyroid-stimulating hormone (TSH) levels should be evaluated. Any thyroid abnormality detected at that time should be treated with conventional therapy. INTRON A treatment may be initiated if TSH levels can be maintained in the normal range by medication.

Monitor hepatic function with serum bilirubin, ALT (alanine transaminase), AST (aspartate aminotransferase), alkaline phosphatase and LDH (lactate dehydrogenase) at 2, 8, and 12 weeks following initiation of INTRON A, then every 6 months while receiving INTRON A. Permanently discontinue INTRON A for evidence of severe (Grade 3) hepatic injury or hepatic decompensation (Child-Pugh score >6 [class B and C]).

If, during the course of INTRON A therapy, a patient develops symptoms consistent with possible thyroid dysfunction, TSH levels should be evaluated. In the presence of thyroid dysfunction, INTRON A treatment may be continued only if TSH levels can be maintained in the normal range by medication. Discontinuation of INTRON A therapy has not reversed thyroid dysfunction occurring during treatment.

INTRON A Solution for Injection should not be administered to patients with chronic hepatitis with decompensated hepatic disease, to patients with autoimmune hepatitis or history of autoimmune disease, or to immunosuppressed transplant recipients because INTRON A therapy may lead to worsening of liver disease in these patients.

Hypotension may occur during INTRON A administration or up to two days post-therapy and may require supportive therapy. Adequate hydration should be maintained in patients undergoing INTRON A therapy since hypotension related to fluid depletion has been seen in some patients. Fluid replacement to maintain intravascular volume may be necessary. Hypertriglyceridaemia and aggravation of hypertriglyceridaemia sometimes severe, have been observed. Monitoring of lipid levels is, therefore, recommended.

Patients with a history of cardiac disease (e.g: congestive heart failure, myocardial infarction and/or previous or current arrhythmic disorders) or with AIDS-related Kaposi's sarcoma, who require INTRON A therapy, should be closely monitored. Cardiomyopathy, sometimes reversible upon discontinuation of interferon alfa, has been reported rarely in AIDS-related Kaposi's
sarcoma patients treated with INTRON A. Those patients who have pre-existing cardiac abnormalities and/or are in advanced stages of cancer, should have electrocardiograms taken prior to and during the course of treatment. Cardiac arrhythmias (primarily supraventricular) occurred rarely and appeared to be correlated with pre-existing conditions and prior therapy with cardiotoxic agents. These adverse experiences usually respond to conventional therapy but may require dose modification or discontinuation of INTRON A therapy.

Cardiomyopathy was reported in approximately 2% of the AIDS-related Kaposi's sarcoma patients treated with INTRON A. Cardiomyopathy has also been reported in AIDS patients not receiving INTRON A therapy. Baseline chest X-rays are suggested and should be repeated if clinically indicated.

Pulmonary infiltrates, pneumonitis and pneumonia, including fatality, have been observed rarely in patients treated with interferon alfa including those treated with INTRON A. The aetiology has not been defined. Any patient developing fever, cough, dyspnœa or other respiratory symptoms should have a chest X-ray taken. If the chest X-ray shows pulmonary infiltrates or there is evidence of pulmonary function impairment, the patient should be monitored closely, and if appropriate, interferon alfa treatment should be discontinued. While this has been reported more often in patients with chronic hepatitis C treated with interferon alfa, it has also been reported in patients with oncologic diseases treated with interferon alfa. Prompt discontinuation of interferon alfa administration and treatment with corticosteroids appear to be associated with resolution of pulmonary adverse events. Moreover, these symptoms have been reported more frequently when shosaikoto, a Chinese herbal medicine, is administered concomitantly with interferon-alfa.

Patients with a pre-existing psychiatric condition, especially depression or a history of severe psychiatric disorder should not be treated with INTRON A.

If severe central nervous system (CNS) effects, particularly depression, are observed, INTRON A therapy should be discontinued. Severe central nervous system (CNS) effects particularly depression, homicidal ideation, suicidal ideation, suicide or attempted suicide have been observed in some patients during INTRON A therapy. Other CNS effects including aggressive behavior, sometimes directed towards others, psychosis including hallucinations, confusion and alterations of mental status have been observed. These adverse effects have occurred in patients treated with recommended doses, as well as in patients treated with higher INTRON A doses. More significant obtundation and coma including cases of encephalopathy, have been observed in some patients, usually elderly, treated at higher doses. While these effects are generally reversible, in a few patients full resolution took up to three weeks. Very rarely seizures have occurred with high doses of INTRON A. If patients develop psychiatric or CNS problems, including clinical depression, it is recommended that the patients be carefully monitored by the prescribing physician during treatment and in the 6 month follow-up period. If such symptoms appear, the potential seriousness of these undesirable effects must be borne in mind by the prescribing physician. If psychiatric symptoms persist or worsen, or suicidal or homicidal ideation or aggressive behaviour towards others is identified, it is recommended that treatment with INTRON A be discontinued, and the patient followed with psychiatric intervention as appropriate. Narcotics, hypnotics or sedatives should be administered with caution if administered concomitantly with INTRON A.

Because of reports of interferon alfa exacerbating pre-existing psoriatic disease and sarcoidosis, INTRON A should be used in patients with psoriasis or sarcoidosis only if the potential benefit justifies the potential risk.

The use of INTRON A has been associated with the exacerbation of autoimmune disease, therefore, when administering INTRON A to patients with a history of, or predisposition to autoimmune disease, this should be considered.
In patients with AIDS-related Kaposi's Sarcoma, INTRON A therapy should not be used in the presence of rapidly progressive visceral disease. With the exception of zidovudine, there is a lack of safety data for the combination of INTRON A with reverse transcriptase inhibitors. Patients receiving concomitant zidovudine have had a higher incidence of neutropenia than that expected with zidovudine alone. The effects of INTRON A when combined with other drugs used in the treatment of AIDS-related disease are unknown.

Ophthalmologic disorders, including retinal haemorrhage, cotton-wool spots, optic neuritis, papilloedema, retinal artery or vein obstruction and serous retinal detachment have been reported rarely in patients treated with interferon alfa, including INTRON A (see Section 4.8). All patients should have a baseline eye examination. Any patient complaining of ocular symptoms, including loss of visual acuity or visual field must have a prompt and complete eye examination. Because these ocular events may occur in conjunction with other disease states, periodic visual examinations during INTRON A therapy are recommended in patients with disorders that may be associated with retinopathy, such as diabetes mellitus or hypertension. Discontinuation of INTRON A therapy should be considered in patients who develop new or worsening ophthalmologic disorders.

Preliminary data indicates that interferon alfa therapy may be associated with an increased rate of kidney graft rejection. Liver graft rejection has also been reported but a causal association with interferon alfa has not been established.

**Paediatric population**
Experience in patients below 18 years of age has been limited and in such cases the expected benefits should be carefully weighed against potential hazards. Results of two studies indicate that the efficacy of interferon therapy remains uncertain in children with chronic active hepatitis B where the presumed route of transmission is vertical.

**Laboratory Tests**
The following laboratory tests should be conducted prior to and periodically during INTRON A treatment for all patients:-

- Standard haematological tests including complete blood counts (CBC), differential white blood cell counts and platelet;
- Blood chemistry including electrolytes, liver function tests, serum creatinine, serum protein and TSH.

The haematological parameters of the patients should be followed closely as part of the treatment because a certain degree of myelodepression has been reported in some patients treated with INTRON A.

Patients with pre-existing thyroid abnormalities may be treated if thyroid stimulating hormone (TSH) levels can be maintained in the normal range by medication. TSH levels must be within normal limits upon initiation of INTRON A treatment and TSH testing should be repeated at 3 and 6 months.

Those patients who have pre-existing cardiac abnormalities and/or who are in advanced stages of cancer should have electrocardiograms taken prior to and during the course of treatment.

**Multiple myeloma**: Since multiple myeloma may impair renal function, patients should have renal tests performed periodically.

**Malignant melanoma**: Liver function and white blood cell (WBC) count and differential should be monitored weekly during the induction phase of therapy and monthly during the maintenance phase of therapy.
**Chronic hepatitis B:** CBC and platelet counts should be evaluated prior to initiation of INTRON A therapy in order to establish baselines for monitoring potential toxicity. These tests should be repeated at treatment Weeks 1, 2, 4, 8, 12 and 16. Liver function tests, including serum ALT, albumin and bilirubin, should be evaluated at treatment Weeks 1, 2, 4, 8, 12 and 16. HBeAg, HBsAg and ALT should be evaluated at the end of therapy as well as 3 and 6 months post therapy, since patients may become virologic responders during the 6 month period following the end of treatment.

A transient increase in ALT ≥2 times baseline value (flare) can occur during INTRON A therapy for chronic hepatitis B. In clinical trials, this flare generally occurred 8 to 12 weeks after initiation of therapy and was more frequent in responders (63%, 24/38) than in non-responders (27%, 13/48). Elevations in bilirubin ≥3 mg/dL (51.3μmol/L) occurred infrequently (2%, 2/86) during therapy.

When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of liver failure are observed. During ALT flare, clinical symptomatology and liver function tests including ALT, prothrombin time, alkaline phosphatase, albumin and bilirubin should be monitored at approximately 2-week intervals.

**Chronic hepatitis C:** Prior to initiation of INTRON A therapy, CBC and platelet counts should be evaluated in order to establish baselines for monitoring potential toxicity. These tests should be repeated at Weeks 1 and 2 following initiation of INTRON A therapy, and monthly thereafter. Serum ALT should be evaluated after 2, 16 and 24 weeks of therapy to assess response to treatment.

### 4.5 Interaction with other medicines and forms of interaction

Interactions between INTRON A and other drugs have not been fully evaluated. Caution should be exercised when administering INTRON A in combination with other potentially myelosuppressive agents.

A synergistic adverse effect on the white blood cell count may occur when INTRON A is administered concomitantly with zidovudine. Patients receiving the two agents concomitantly have had a dose-dependent higher incidence of neutropenia than expected when zidovudine is administered alone.

[See Concomitant Therapy under Section 4.2]

### 4.6 Fertility, pregnancy and lactation

**Pregnancy (Category B3)**

Results of animal reproduction studies indicate that recombinant interferon alfa-2b was not teratogenic in rats or rabbits, nor did it adversely affect pregnancy, foetal development or reproductive capacity in the offspring of treated rats. Animal studies have also shown that interferons do not cross the placental barrier.

Interferon has been shown to have abortifacient effects in rhesus monkeys (*Macaca mulatta*). Abortion was observed in all dose groups (7.5, 15 and 30 million IU/day IM from Day 20 to Day 80 of gestation), and was statistically significant versus control in the mid- and high-dose groups.
There are no adequate and well controlled studies in pregnant women. INTRON A should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.

**Breast-feeding**

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for adverse reactions from INTRON A in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

**Fertility**

Interferon may impair fertility. In studies on interferon use in non-human primates, abnormalities of the menstrual cycle have been observed. Decreased serum oestradiol and progesterone concentrations have been reported in women treated with human leucocyte interferon. Therefore, fertile women should not receive INTRON A unless they are using effective contraception during the treatment period. INTRON A should be used with caution in fertile men.

**4.7 Effects on ability to drive and use machines**

Not relevant.

**4.8 Undesirable effects**

**Summary of the safety profile**

Adverse reactions of INTRON A are dose-related. Haematological, hepatic, cardiovascular and neurological toxicities are more common with higher doses.

The most frequently reported adverse reactions were flu-like symptoms, primarily fever, fatigue, headache, myalgia, rigors/chills and malaise which occurred in almost all patients treated. These effects were reversible within 72 hours of interruption or cessation of treatment and were dose-related. While fever may be related to the flu-like symptoms commonly reported in patients treated with interferons, other causes of persistent fever should be excluded.

A wide variety of autoimmune and immune-mediated disorders have been reported with alfa interferons including idiopathic thrombocytopenic purpura and thrombotic thrombocytopenic purpura, rheumatoid arthritis, systemic lupus erythematosus, vasculitis, and Vogt-Koyanogi-Harada syndrome.

Cases of acute hypersensitivity reactions, including anaphylaxis, urticaria, and angioedema have been reported.

Asthенич conditions (including asthenia, malaise and fatigue), homicidal ideation, dehydration, palpitations, psoriasis, fungal infection, and bacterial infection (including sepsis), have been reported.

When INTRON A is used with hydroxyurea, the occurrence of cutaneous vasculitides may be increased.

Cases of pulmonary arterial hypertension (PAH) have been reported with interferon alfa products, notably in patients with risk factors for PAH (such as portal hypertension, HIV-
infection, cirrhosis). Events were reported at various time points typically several months after starting treatment with interferon alfa.

**Laboratory Values**
Clinically significant laboratory abnormalities, most frequently occurring at doses greater than 10 million IU daily, include reduction in granulocyte and white blood cell counts; decreases in haemoglobin level and platelet count; increases in alkaline phosphatase, lactate dehydrogenase (LDH), serum creatinine, serum urea nitrogen levels and TSH levels. Moderate and usually reversible reduction in all three blood elements – white blood cells, red blood cells and platelets, have been reported. Increase in serum ALT/AST levels have been noted as an abnormality in some non-hepatitis subjects and also in some patients with hepatitis particularly those with chronic hepatitis B coincident with clearance of viral DNAp.

**Tabulated list of adverse reactions**
[common (1/100 to <1/10); uncommon (1/1,000 to <1/100); rare (1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data)]

<table>
<thead>
<tr>
<th>Infections and infestations</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Rare</td>
<td>Resistance mechanism disorders (e.g. altered resistance to infections; these effects rarely have been life-threatening or fatal) viral infections, conjunctivitis, Herpes simplex</td>
</tr>
<tr>
<td>Very rare</td>
<td>Sty, fungal infections, moniliasis, sepsis</td>
</tr>
<tr>
<td>Not known</td>
<td>hepatitis B reactivation in HCV/HBV co-infected patients</td>
</tr>
</tbody>
</table>

**Blood and lymphatic system disorders**

| Very rare                                       | Haemolytic anaemia, increased gamma globulins, coagulation disorder, lymphadenopathy  |
|                                                 | Very rarely, alfa interferons, including INTRON A used alone or in combination with Rebetol may be associated with aplastic anaemia or pure red cell aplasia. |
|                                                 | [See Laboratory Values under Section 4.8]                                      |

**Immune system disorders**

| Very rare                                       | Transplant rejection, sarcoidosis or exacerbation of sarcoidosis               |

**Endocrine disorders**

| Rare                                            | Hyperthyroidism, hypothyroidism, diabetes mellitus/hyperglycaemia              |
| Very rare                                       | Gynaecomastia, virilism, aggravation of diabetes, pancreatitis                 |

**Metabolism and nutrition disorders**

| Common                                          | Anorexia                                                                 |
| Rare                                            | Increased appetite                                                      |
| Very rare                                       | Dehydration, hypercalcaemia, cachexia, acidosis, hypertriglyceridaemia     |

**Psychiatric disorders**
<table>
<thead>
<tr>
<th>Frequency</th>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncommon</td>
<td>Insomnia, confusion, depression, irritability, suicidal ideation, suicide attempts, suicide</td>
</tr>
<tr>
<td>Rare</td>
<td>Nervousness, anxiety, agitation, emotional lability, psychosis including hallucinations, aggressive behaviour sometimes directed towards others, decreased libido</td>
</tr>
<tr>
<td>Very rare</td>
<td>Personality disorder, impotence, abnormal thinking, paroniria, apathy, aggravated depression, neurosis,</td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Uncommon</td>
<td>Dizziness, somnolence, impaired concentration, taste alteration</td>
</tr>
<tr>
<td>Rare</td>
<td>Paraesthesia, impaired consciousness (including cases of encephalopathy, see Section 4.4), migraine, hypo-aesthesia, seizures, neuropathy, peripheral neuropathy, polyneuropathy</td>
</tr>
<tr>
<td>Very rare</td>
<td>Amnesia, stupor, convulsions, hypertonia, hyperaesthesia, hot flushes, encephalopathy, tremor, coma, extrapyramidal disorder, paresis, speech disorder, syncope, tinnitus, abnormal coordination, ataxia, aphasia, CNS dysfunction, abnormal gait, hyperkinesia, dystonia, paralysis, feeling of ebriety, dementia</td>
</tr>
<tr>
<td><strong>Eye disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Rare</td>
<td>Eye pain, abnormal/blurred vision, retinal haemorrhage, retinopathies (including macular oedema), cotton wool spots, and retinal artery or vein obstruction, loss of visual acuity or visual field, optic neuritis and papilloedema, lacrimal gland disorder</td>
</tr>
<tr>
<td>Very rare</td>
<td>Conjunctivitis, photophobia, diplopia, dry eyes, oculomotor nerve paralysis, retinal disorder, night blindness, and serous retinal detachment, periorbital oedema</td>
</tr>
<tr>
<td><strong>Ear and labyrinth disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Rare</td>
<td>Hearing disorder, hearing loss, vertigo</td>
</tr>
<tr>
<td>Very Rare</td>
<td>Earache, deafness, hyperacusis</td>
</tr>
<tr>
<td><strong>Cardiac disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Uncommon</td>
<td>Hypotension</td>
</tr>
<tr>
<td>Rare</td>
<td>Tachycardia, hypertension, peripheral ischaemia, chest pain, flushing, cardiomyopathy (see below)</td>
</tr>
<tr>
<td>Very rare</td>
<td>Palpitations, postural hypotension, bradycardia, cardiac failure, atrial fibrillation, arrhythmia, extrasystole, angina pectoris, thrombophlebitis, cardiac ischaemia, myocardial infarction, cerebrovascular haemorrhage, cerebrovascular ischemia.</td>
</tr>
<tr>
<td>Not known</td>
<td>pericarditis</td>
</tr>
<tr>
<td><strong>Respiratory, thoracic and mediastinal disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Rare</td>
<td>Coughing, pharyngitis, dyspnoea, pulmonary infiltrates, pneumonitis, pneumonia, nasal congestion, sinusitis, rhinitis, respiratory disorder, epistaxis.</td>
</tr>
<tr>
<td>Frequency</td>
<td>Symptoms</td>
</tr>
<tr>
<td>-----------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Very rare</td>
<td>Hypoxia, stridor, bronchospasm, cyanosis, wheezing, pleural pain, sneezing, non-productive coughing, pulmonary embolism, pulmonary oedema, laryngitis.</td>
</tr>
<tr>
<td>Not known</td>
<td>Pulmonary fibrosis</td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Common</td>
</tr>
<tr>
<td></td>
<td>Nausea</td>
</tr>
<tr>
<td>Uncommon</td>
<td>Vomiting, diarrhoea, dry mouth</td>
</tr>
<tr>
<td>Rare</td>
<td>Abdominal pain, dyspepsia, loose stool, taste perversion, gingival bleeding, stomatitis, constipation, right upper quadrant (RUQ) pain, glossitis.</td>
</tr>
<tr>
<td>Very rare</td>
<td>Colitis, eructation, tenesmus, ileus, thirst, melena, increased saliva, esophagitis, rectal bleeding after stool, dysphagia, gastrointestinal haemorrhage, gastric ulcer, gingivitis, gum hyperplasia, rectal haemorrhage, oral leucoplaikia, gastrointestinal mucosal discolouration, abdominal distention, flatulence, tongue discolouration, taste loss, tongue pigmentation.</td>
</tr>
<tr>
<td>Not known</td>
<td>Tongue pigmentation</td>
</tr>
<tr>
<td><strong>Hepatobiliary disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Rare</td>
<td>Hepatotoxicity including fatality</td>
</tr>
<tr>
<td>Very rare</td>
<td>Abnormal hepatic function tests, bilirubinaemia, jaundice, hepatospleno-megaly, splenomegaly, hepatic encephalopathy</td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Uncommon</td>
<td>Alopecia, increased sweating</td>
</tr>
<tr>
<td>Rare</td>
<td>Rash (e.g. erythematous and maculopapular), injection site disorders (to routes of administration other than intralesional), pruritus, dermatitis, dry skin, erythema</td>
</tr>
<tr>
<td>Very rare</td>
<td>Urticaria, acne, nail disorders, purpura, peripheral ischaemia, furunculosis, non-herpetic cold sores, epidermal necrolysis, lacrimal gland disorder, photosensitivity, skin discolouration, chloasma, abnormal hair texture, increased hair growth, skin depigmentation, dermatitis lichenoides, melanosis, vitiligo, injection site necrosis, toxic epidermal necrolysis, erythema multiforme, Stevens Johnson syndrome</td>
</tr>
<tr>
<td><strong>Musculoskeletal and connective tissue disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Arthralgia, back pain</td>
</tr>
<tr>
<td>Uncommon</td>
<td>Musculoskeletal pain</td>
</tr>
<tr>
<td>Rare</td>
<td>Rhabdomyolysis (sometimes serious), myositis, leg cramps</td>
</tr>
<tr>
<td>Very rare</td>
<td>Bone pain, muscle weakness, arthritis, arthrosis, myopathy</td>
</tr>
<tr>
<td><strong>Renal and urinary disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Rare</td>
<td>Renal insufficiency, renal failure, hyperuricaemia</td>
</tr>
<tr>
<td>Very rare</td>
<td>Micturition disorder, nocturia, polyuria, haematuria, micturition frequency, cystitis, oliguria, nephrosis, urinary incontinence, nephrotic syndrome</td>
</tr>
<tr>
<td><strong>Reproductive system and breast disorders</strong></td>
<td></td>
</tr>
</tbody>
</table>
Rare | Menstrual disorders e.g. menorrhagia, amenorrhoea
Very rare | Leucorrhoea, uterine bleeding, vaginal haemorrhage

**General disorders and administration site conditions**

Uncommon | Asthenia, flu-like symptoms (unspecified), pain
Rare | Weakness, face oedema
Very rare | peripheral oedema, malignant hyperpyrexia

**Investigations**

Rare | weight decrease

* Cardiovascular adverse reactions, particularly arrhythmia appeared to be correlated mostly with pre-existing CVS disease and prior cardiotoxic therapy (see Section 4.4). Cardiomyopathy that may be reversible upon discontinuation of interferon alfa has been reported rarely in patients without prior evidence of cardiac disease.

**4.9 Overdose**

Most adverse reactions to recombinant interferon alfa-2b listed are dose-related. There is no specific antidote in the event of overdose. Symptomatic treatment with frequent monitoring of vital signs and close observation of the patient is indicated.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: L; ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS, L03; IMMUNOSTIMULANTS, L03A; IMMUNOSTIMULANTS, L03AB; Interferons, ATC code: L03AB05

**Mechanism of action**

Interferons are a family of naturally occurring, small protein molecules produced and secreted by cells in response to viral infections or various synthetic and biological inducers.

Interferons exert their cellular activities by binding to specific membrane receptors on the cell surface. Preliminary studies to characterise these membrane receptors and to determine the subsequent fate of the human interferon-receptor complex have been carried out using 

$^{125}$I-labelled recombinant interferon alfa-2b. Human interferon receptors, as isolated from human lymphoblastoid (Daudi) cells, appear to be highly asymmetric membrane proteins. They exhibit selectivity for human but not murine interferons, suggesting species specificity. Studies with other interferons have demonstrated species specificity.
The results of several studies suggest that, once bound to the cell membrane, the interferon initiates a complex sequence of intracellular events which include the induction of certain enzymes. It is thought that this process, at least in part, is responsible for the various cellular responses to interferons, including inhibition of virus replication in virus-infected cells, suppression of cell proliferation and such immunomodulating activities as enhancement of the phagocytic activity of macrophages and augmentation of the specific cytotoxicity of lymphocytes for target cells. These activities possibly contribute to the therapeutic effects of interferons.

Recombinant interferon alfa-2b has exhibited antiproliferative effects in preclinical studies employing both cell culture systems and human tumour xenografts in animals, and has demonstrated significant immunomodulatory activity in vitro. Recombinant interferon alfa-2b also inhibits viral replication in vitro and in vivo.

The antiproliferative activity of recombinant interferon alfa-2b was evaluated in vitro using mouse and human leukaemia cell lines, and human osteosarcoma, melanoma, and normal amnion cells. The antiproliferative activity of recombinant interferon alfa-2b was most pronounced against human osteosarcoma cells and the human lymphocytic leukaemia cell line RPMI-8402; growth of both cell lines was inhibited 80-100%. No activity was seen in mouse leukaemia cells, which again suggests species specificity.

The immunomodulating activity of recombinant interferon alfa-2b was demonstrated in vitro by its augmentation of the spontaneous "natural killer" activity of human lymphocytes, its enhancement of the tumoricidal activity of human monocytes against human tumour cells and its induction of Class I histocompatibility antigens on the surface of a number of cell types. These effects appear to be dose-dependent.

Recombinant interferon alfa-2b injected intralesionally (0.2 or 0.8 million IU/day for 7 days) delayed the development and reduced the volume of human osteosarcoma implants in athymic mice. The effect was dose-related. Additionally, subcutaneous administration of recombinant interferon alfa-2b at a dose of 0.2 million IU/day inhibited the growth of implanted human breast tumour xenografts in athymic mice by about 50% after 23 days. However, intra-peritoneal administration of recombinant interferon alfa-2b (0.1 - 1 million IU for 9 days) demonstrated no effect on the growth of human tumour xenografts in athymic mice or on murine leukaemia cells implanted in BDF1 mice.

A human tumour stem cell assay was used to study the effects of recombinant interferon alfa-2b in combination with doxorubicin. Study results suggested that a schedule-dependent synergistic effect was exhibited when doxorubicin and recombinant interferon alfa-2b were combined in the cell lines tested. Antagonistic effects or cell growth enhancement over control levels were not observed.

Preliminary studies with isolated and perfused rabbit kidneys have shown that the kidney may be the main site of interferon alfa catabolism.

Clinical efficacy and safety
Kaposi's Sarcoma: In patients with AIDS-related Kaposi’s sarcoma, measures of immunologic competence, commonly characterised by the baseline T4 count or T4/T8 ratio, have been noted to be highly predictive of the status of AIDS patients and their likelihood of response to INTRON A treatment. In patients with baseline T4 counts above 400, the overall response rate to INTRON A can be expected to be as high as 78%. Few patients with baseline T4 counts less than 200 can be expected to respond to INTRON A.

Chronic hepatitis B: Studies in patients with compensated liver disease and evidence of chronic hepatitis B virus infection (serum HBsAg positive) and HBV replication (serum HBeAg positive and serum HBV-DNA positive) have demonstrated that INTRON A therapy can produce
virologic remission of this disease (loss of serum HBeAg) and normalisation of serum aminotransferases.

In clinical studies, 39% (15/38) of responding patients lost HBeAg 1 to 6 months following the end of INTRON A therapy. Virologic response was associated with a reduction in serum ALT to normal or near normal (≤1.5 times the upper limit of normal) in 87% (13/15) of patients responding to INTRON A therapy at 5 million IU daily. Of responding patients who lost HBsAg, 58% (7/12) did so 1 to 6 months post-treatment.

**Chronic hepatitis C:** Studies in patients with compensated liver disease and a history of blood or blood product exposure and/or positive HCV antibody demonstrated that INTRON A therapy can produce clinically meaningful effects on this disease, manifested by normalisation of serum ALT and reduction in liver necrosis and degeneration.

A multicentre study comparing treatment of chronic hepatitis C using INTRON A (i) 3 million IU three times weekly for a duration of 18 months, (ii) 3 million IU three times weekly for 6 months then 1 million IU three times weekly for 12 months and (iii) 3 million IU three times weekly for 6 months showed that treatment with 3 million IU three times weekly for a duration of 18 months produced significantly superior histological improvement, virological response and sustained ALT response than the regimens involving a lower dose or shorter duration of treatment.

Similarly, an Australian multicentre study evaluated the efficacy of INTRON A (i) 3 million IU three times weekly for 6 months, (ii) 5 million IU three times weekly for 6 months and (iii) 3 million IU three times weekly for 24 months. Treatment for a duration of up to 24 months significantly improved the sustained response in patients who achieved normalisation of ALT at 24 weeks of therapy compared to the two 6-month treatment regimens. Sustained ALT response was associated with virological response and improvement in hepatic inflammation. This study confirmed that INTRON A 3 million IU three times weekly remains the optimal dose; increasing the dose to 5 million IU three times weekly did not significantly improve the ALT response rate or sustained ALT response.

**Malignant melanoma:** The safety and efficacy of INTRON A was evaluated as adjuvant to surgical treatment in patients with melanoma who were free of disease (post-surgery) but at high risk for systemic recurrence. These included patients with lesions of Breslow thickness >4 mm, or patients with lesions of any Breslow thickness with primary or recurrent nodal involvement. In a randomised, controlled trial in 280 patients, 143 patients received INTRON A therapy at 20 million IU/m² intravenously five times per week for 4 weeks (induction phase) followed by 10 million IU/m² subcutaneously three times per week for 48 weeks (maintenance phase). INTRON A therapy was begun ≤56 days after surgical resection. The remaining 137 patients were observed.

INTRON A therapy produced a significant increase in relapse-free and overall survival. Median time to relapse for the INTRON A treated patients versus observation patients was 1.72 years versus 0.98 years (p=0.01, stratified Log Rank). The estimated 5-year relapse-free survival rate, using the Kaplan-Meier method, was 37% for INTRON A treated patients versus 26% for observation patients. Median overall survival time for INTRON A treated patients was 3.82 years versus 2.78 years (p=0.047, stratified Log Rank). The estimated 5-year overall survival rate, using the Kaplan-Meier method, was 46% for INTRON A treated patients versus 37% for observation patients.

The INTRON A dose was modified because of adverse events in 65% (n=93) of the patients. INTRON A therapy was discontinued because of adverse events in 8% of the patients during induction and 18% of the patients during maintenance. The most frequently reported adverse reaction was fatigue which was observed in 96% of patients. Other adverse reactions that were recorded in >20% of INTRON A treated patients included neutropenia (92%), fever (81%), myalgia (75%), anorexia (69%), vomiting/nausea (66%), increased SGOT (63%), headache (62%), chills (54%), depression (40%), diarrhoea (35%), alopecia (29%), altered taste sensation (24%), dizziness/vertigo (23%), and anaemia (22%).
Adverse reactions classified as severe or life-threatening (ECOG Toxicity Criteria grade 3 or 4) were recorded in 66% and 14% of INTRON A treated patients, respectively. Severe adverse reactions recorded in >10% of INTRON A treated patients included neutropenia/leucopenia (26%), fatigue (23%), fever (18%), myalgia (17%), headache (17%), chills (16%), and increased SGOT (14%). Grade 4 fatigue was recorded in 4% and grade 4 depression was recorded in 2% of INTRON A treated patients. No other grade 4 adverse event was reported in more than 2 INTRON A treated patients. Lethal hepatotoxicity occurred in 2 INTRON A treated patients early in the clinical trial. No subsequent lethal hepatotoxicities were observed with adequate monitoring of liver function tests.

5.2 Pharmacokinetic properties
The pharmacokinetics of INTRON A after single doses administered subcutaneously, intramuscularly and as a 30-minute intravenous infusion has been studied in healthy male volunteers. In one study involving 12 subjects, single 5 million IU/m² doses were administered by the three routes. Serum concentrations of interferon alfa-2b were determined by a radio-immunoassay (RIA) with a detection limit of 10 IU/mL. The mean serum interferon concentrations following subcutaneous and intramuscular injections were comparable. Maximum serum levels (18-116 IU/mL) occurred at 3 to 12 hours post-injection. The elimination half-lives of interferon following both injections were 2 to 3 hours. Serum levels were below the detection limit 16 hours post-injection.

After intravenous administration, serum interferon levels peaked (135-273 IU/mL) at the end of the infusion, then declined at a slightly more rapid rate than after subcutaneous or intramuscular administration, becoming undetectable 4 hours after the infusion. The elimination half-life was approximately 2 hours.

In another study also involving 12 subjects, single 10 million IU doses were administered by the same three routes of administration. Mean serum interferon concentrations were again comparable following intramuscular and subcutaneous injections, with maximum serum levels (150-180 IU/mL) occurring at 6 to 8 hours post-injection. The elimination half-lives following both injections were 6 to 7 hours. Serum levels were below the detection limit of 25 IU/mL 24 hours post-injection.

As with the other study, after intravenous administration, serum interferon levels peaked (546 IU/mL) at the end of the infusion, then declined rapidly with time, becoming undetectable 4 hours after the infusion.

Urine levels of interferon were below the detection limit following each of the three routes of administration in both studies.

Interferon neutralising factor assays were performed on serum samples of patients who received INTRON A in Schering Plough monitored clinical trials. The clinical incidence of neutralising factors developing in cancer patients treated systemically is 2.9% and in hepatitis patients, 6.9%. The detected titres are low in almost all cases and have not been regularly associated with loss of response or any other autoimmune phenomenon.

5.3 Preclinical safety data
See Section 4.6
6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients
sodium phosphate dibasic
sodium phosphate monobasic
disodium edetate
sodium chloride
meta cresol
polysorbate 80
water for injections

6.2 Incompatibilities
Not applicable.

6.3 Shelf life
15 months.
48 hours not refrigerated stored at or below 30°C.
In-use, 4 weeks stored as directed between doses (see Section 4.2).

6.4 Special precautions for storage
Store at 2°C to 8°C (Refrigerate, do not freeze).
For storage conditions after first use of the medicine, see section 6.3.

6.5 Nature and contents of container
See Section 3.

6.6 Special precautions for disposal
No special requirements for disposal.

7. MEDICINE SCHEDULE
Prescription

8. SPONSOR
Merck Sharp & Dohme (New Zealand) Limited
P O Box 99 851
Newmarket
9. DATE OF FIRST APPROVAL
11 March 1998

10. DATE OF REVISION OF THE TEXT
14 December 2017

Summary table of changes

<table>
<thead>
<tr>
<th>Section changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>Reformat to New Zealand data sheet template</td>
</tr>
<tr>
<td>4.8</td>
<td>Addition of ‘tongue pigmentation’</td>
</tr>
</tbody>
</table>